BACKGROUND: Acetaminophen (paracetamol) is a widely used over-the-counter drug, but concerns of genotoxic effects have been raised. After we recently found an almost two-fold increased risk of hematologic malignancies associated with high use of acetaminophen in the prospective VITamins And Lifestyle (VITAL) study, we herein further examined the association between acetaminophen use and cancer risk in the VITAL cohort. METHODS: A total of 62,841 men and women aged 50 to 76 years were recruited from 2000 to 2002, and incident malignancies other than nonmelanoma skin cancer (n = 5,750) were identified through December 2008 via linkage to the Surveillance, Epidemiology, and End Results cancer registry. HRs associated with acetaminophen use for incidence of total cancers and nonhematologic cancer subcategories were estimated with Cox proportional hazards models that were adjusted for age, demographics, cancer risk factors, and medical conditions that may be indications for acetaminophen use. RESULTS: Use of acetaminophen was not associated with total cancer risk. We also observed no associations for most major nonhematologic cancer sites, including cancers of the gastrointestinal system, lung, urinary tract, skin, prostate, or female organs. CONCLUSION: This study failed to provide evidence of an association between acetaminophen use and total cancer risk or incidence of nonhematologic malignancies. IMPACT: Together with our previous findings, the analyses from the VITAL study suggest a particular sensitivity of the hematopoietic system to the mutagenic effects of acetaminophen.
BACKGROUND:Acetaminophen (paracetamol) is a widely used over-the-counter drug, but concerns of genotoxic effects have been raised. After we recently found an almost two-fold increased risk of hematologic malignancies associated with high use of acetaminophen in the prospective VITamins And Lifestyle (VITAL) study, we herein further examined the association between acetaminophen use and cancer risk in the VITAL cohort. METHODS: A total of 62,841 men and women aged 50 to 76 years were recruited from 2000 to 2002, and incident malignancies other than nonmelanoma skin cancer (n = 5,750) were identified through December 2008 via linkage to the Surveillance, Epidemiology, and End Results cancer registry. HRs associated with acetaminophen use for incidence of total cancers and nonhematologic cancer subcategories were estimated with Cox proportional hazards models that were adjusted for age, demographics, cancer risk factors, and medical conditions that may be indications for acetaminophen use. RESULTS: Use of acetaminophen was not associated with total cancer risk. We also observed no associations for most major nonhematologic cancer sites, including cancers of the gastrointestinal system, lung, urinary tract, skin, prostate, or female organs. CONCLUSION: This study failed to provide evidence of an association between acetaminophen use and total cancer risk or incidence of nonhematologic malignancies. IMPACT: Together with our previous findings, the analyses from the VITAL study suggest a particular sensitivity of the hematopoietic system to the mutagenic effects of acetaminophen.
Authors: Eric J Jacobs; Christina C Newton; Victoria L Stevens; Susan M Gapstur Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-05-17 Impact factor: 4.254
Authors: Søren Friis; Gunnar Lauge Nielsen; Lene Mellemkjaer; Joseph K McLaughlin; Ane Marie Thulstrup; William J Blot; Loren Lipworth; Hendrik Vilstrup; Jørgen H Olsen Journal: Int J Cancer Date: 2002-01-01 Impact factor: 7.396
Authors: Emily White; Ruth E Patterson; Alan R Kristal; Mark Thornquist; Irena King; Ann L Shattuck; Ilonka Evans; Jessie Satia-Abouta; Alyson J Littman; John D Potter Journal: Am J Epidemiol Date: 2004-01-01 Impact factor: 4.897
Authors: P M Webb; R Na; E Weiderpass; H O Adami; K E Anderson; K A Bertrand; E Botteri; T M Brasky; L A Brinton; C Chen; J A Doherty; L Lu; S E McCann; K B Moysich; S Olson; S Petruzella; J R Palmer; A E Prizment; C Schairer; V W Setiawan; A B Spurdle; B Trabert; N Wentzensen; L Wilkens; H P Yang; H Yu; H A Risch; S J Jordan Journal: Ann Oncol Date: 2019-02-01 Impact factor: 32.976
Authors: Sara Karami; Sarah E Daughtery; Kendra Schwartz; Faith G Davis; Julie J Ruterbusch; Sholom Wacholder; Barry I Graubard; Sonja I Berndt; Jonathan N Hofmann; Mark P Purdue; Lee E Moore; Joanne S Colt Journal: Int J Cancer Date: 2016-04-09 Impact factor: 7.396
Authors: Angelina Huseinovic; Jolanda S van Leeuwen; Tibor van Welsem; Iris Stulemeijer; Fred van Leeuwen; Nico P E Vermeulen; Jan M Kooter; J Chris Vos Journal: PLoS One Date: 2017-03-14 Impact factor: 3.240
Authors: Angelina Huseinovic; Stefan J Dekker; Bob Boogaard; Nico P E Vermeulen; Jan M Kooter; J Chris Vos Journal: Amino Acids Date: 2018-07-05 Impact factor: 3.520